{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:06:34Z","timestamp":1789592794356,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L244064"],"award-info":[{"award-number":["L244064"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["L234020"],"award-info":[{"award-number":["L234020"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470966"],"award-info":[{"award-number":["32470966"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["32470966"],"award-info":[{"award-number":["32470966"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023TQ0016"],"award-info":[{"award-number":["2023TQ0016"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZC20230135"],"award-info":[{"award-number":["GZC20230135"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2023TQ0016"],"award-info":[{"award-number":["2023TQ0016"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"publisher"}]},{"award":["GZC20230135"],"award-info":[{"award-number":["GZC20230135"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Many patients develop poor clinical response to immune checkpoint inhibitors (ICIs), especially PD-1\/PD-L1 blockade. However, transcriptomic features of chemokine receptors associated with poor response remain incompletely characterized. We analyzed publicly available single-cell RNA sequencing datasets from non-small-cell lung cancer (NSCLC) and melanoma cohorts, with additional exploratory analyses in hepatocellular carcinoma (HCC) and colorectal cancer datasets. Chemokine receptor expression on CD8+ T cells from clinical responsive and non-responsive samples to anti-PD-1 therapy was systematically profiled. Differential gene expression, cell-state scoring, pseudotime trajectory inference, and ligand\u2013receptor interaction analysis were performed to characterize associated transcriptional states and predicted cellular interactions. CCR5 transcript expression in tumor-infiltrating CD8+ T cells was associated with lower responsiveness to PD-1\/PD-L1 blockade therapy. CCR5+ CD8+ T cells exhibited transcriptional features associated with increased exhaustion, reduced stemness, and advanced differentiation. Pseudotime inference suggested progressively increased CCR5 expression along the inferred differentiation trajectory. Ligand\u2013receptor interaction analysis further identified predicted interactions between CCR5+ CD8+ T cells and tumor-associated myeloid cells, with elevated expression of CCL3 and CCL4 observed in myeloid populations from non-responsive tumors. Together, these findings identify transcriptomic associations between CCR5+ CD8+ T cell states and poor clinical response to PD-1 blockade therapy. These observations support the CCL3\/4\u2013CCR5 axis as a candidate pathway for future spatial, functional, and experimental validation.<\/jats:p>","DOI":"10.3390\/ijms27114963","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:45:08Z","timestamp":1780404308000},"page":"4963","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy"],"prefix":"10.3390","volume":"27","author":[{"given":"Ziheng","family":"Zhao","sequence":"first","affiliation":[{"name":"NHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Liu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-6449","authenticated-orcid":false,"given":"Zhaofei","family":"Wu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunliang","family":"Qi","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingze","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Lin","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Pang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-1892","authenticated-orcid":false,"given":"Guangliang","family":"Qiang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Medical Immunology, Department of Immunology, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13115","DOI":"10.1111\/cpr.13115","article-title":"Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Prolif."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","article-title":"A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Yizhak","year":"2018","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell\u2013CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cellsig.2004.04.007","article-title":"Chemokine receptor CCR5: Insights into structure, function, and regulation","volume":"16","author":"Oppermann","year":"2004","journal-title":"Cell Signal."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: Positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e007939","DOI":"10.1136\/jitc-2023-007939","article-title":"CCR5 and CCL5 gene expression in colorectal cancer: Comprehensive profiling and clinical value","volume":"12","author":"Battaglin","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Buggert, M., Tauriainen, J., Yamamoto, T., Frederiksen, J., Ivarsson, M.A., Micha\u00eblsson, J., Lund, O., Hejdeman, B., Jansson, M., and S\u00f6nnerborg, A. (2014). T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004251"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","article-title":"Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection","volume":"359","author":"Nelson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(06)69157-5","article-title":"HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment","volume":"368","author":"Simon","year":"2006","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2020.01.009","article-title":"The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction","volume":"474","author":"Huang","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/0008-5472.CAN-17-0915","article-title":"CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion","volume":"78","author":"Jiao","year":"2018","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2020.38.15_suppl.3010","article-title":"Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial","volume":"38","author":"Haag","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1038\/s41467-025-59890-0","article-title":"In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome","volume":"16","author":"Mizumaki","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41590-018-0311-z","article-title":"The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity","volume":"20","author":"Gautam","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rigopoulos, C., Georgakopoulos-Soares, I., and Zaravinos, A. (2024). A Multi-Omics Analysis of an Exhausted T Cells\u2019 Molecular Signature in Pan-Cancer. J. Pers. Med., 14.","DOI":"10.3390\/jpm14070765"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4963\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:58:00Z","timestamp":1780405080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/4963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27114963"],"URL":"https:\/\/doi.org\/10.3390\/ijms27114963","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]}}}